LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer

Mengxing Li; Suryavathi Viswanadhapalli; Bindu Santhamma; Uday P. Pratap; Yiliao Luo; Junhao Liu; Kristin A. Altwegg; Weiwei Tang; Zexuan Liu; Xiaonan Li; Behnam Ebrahimi; Hui Yan; Yi Zou; Swapna Konda; Gangadhara R. Sareddy; Zhenming Xu; Yidong Chen; Manjeet K. Rao; Andrew J. Brenner; Virginia G. Kaklamani; Rajeshwar R. Tekmal; Gulzar Ahmed; Ganesh V. Raj; Klaus J. Nickisch; Hareesh B. Nair; Ratna K. Vadlamudi

doi:10.1038/s42003-021-02741-7

LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer

Mengxing Li, Suryavathi Viswanadhapalli, Bindu Santhamma, Uday P. Pratap, Yiliao Luo, Junhao Liu, Kristin A. Altwegg, Weiwei Tang, Zexuan Liu, Xiaonan Li, Behnam Ebrahimi, Hui Yan, Yi Zou, Swapna Konda, Gangadhara R. Sareddy, Zhenming Xu, Yidong Chen, Manjeet K. Rao, Andrew J. Brenner, Virginia G. KaklamaniRajeshwar R. Tekmal, Gulzar Ahmed, Ganesh V. Raj, Klaus J. Nickisch, Hareesh B. Nair, Ratna K. Vadlamudi

Producción científica: Article › revisión exhaustiva

17 Citas (Scopus)

Resumen

Histone deacetylase inhibitors (HDACi) are identified as novel therapeutic agents, however, recent clinical studies suggested that they are marginally effective in treating triple negative breast cancer (TNBC). Here, we show that first-in-class Leukemia Inhibitory Factor Receptor (LIFRα) inhibitor EC359 could enhance the therapeutic efficacy of HDACi against TNBC. We observed that both targeted knockdown of LIFR with CRISPR or treatment with EC359 enhanced the potency of four different HDACi in reducing cell viability, cell survival, and enhanced apoptosis compared to monotherapy in TNBC cells. RNA-seq studies demonstrated oncogenic/survival signaling pathways activated by HDACi were attenuated by the EC359 + HDACi therapy. Importantly, combination therapy potently inhibited the growth of TNBC patient derived explants, cell derived xenografts and patient-derived xenografts in vivo. Collectively, our results suggest that targeted inhibition of LIFR can enhance the therapeutic efficacy of HDACi in TNBC.

Idioma original	English (US)
Número de artículo	1235
Publicación	Communications Biology
Volumen	4
N.º	1
DOI	https://doi.org/10.1038/s42003-021-02741-7
Estado	Published - dic 2021

ASJC Scopus subject areas

Medicine (miscellaneous)
General Biochemistry, Genetics and Molecular Biology
General Agricultural and Biological Sciences

Acceder al documento

10.1038/s42003-021-02741-7

Otros archivos y enlaces

Citar esto

Li, M., Viswanadhapalli, S., Santhamma, B., Pratap, U. P., Luo, Y., Liu, J., Altwegg, K. A., Tang, W., Liu, Z., Li, X., Ebrahimi, B., Yan, H., Zou, Y., Konda, S., Sareddy, G. R., Xu, Z., Chen, Y., Rao, M. K., Brenner, A. J., ... Vadlamudi, R. K. (2021). LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer. Communications Biology, 4(1), Artículo 1235. https://doi.org/10.1038/s42003-021-02741-7

Li, M, Viswanadhapalli, S, Santhamma, B, Pratap, UP, Luo, Y, Liu, J, Altwegg, KA, Tang, W, Liu, Z, Li, X, Ebrahimi, B, Yan, H, Zou, Y, Konda, S, Sareddy, GR , Xu, Z , Chen, Y , Rao, MK , Brenner, AJ , Kaklamani, VG , Tekmal, RR, Ahmed, G, Raj, GV, Nickisch, KJ, Nair, HB & Vadlamudi, RK 2021, 'LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer', Communications Biology, vol. 4, n.º 1, 1235. https://doi.org/10.1038/s42003-021-02741-7

@article{79ee218676f94f579733ec712e07195a,

title = "LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer",

abstract = "Histone deacetylase inhibitors (HDACi) are identified as novel therapeutic agents, however, recent clinical studies suggested that they are marginally effective in treating triple negative breast cancer (TNBC). Here, we show that first-in-class Leukemia Inhibitory Factor Receptor (LIFRα) inhibitor EC359 could enhance the therapeutic efficacy of HDACi against TNBC. We observed that both targeted knockdown of LIFR with CRISPR or treatment with EC359 enhanced the potency of four different HDACi in reducing cell viability, cell survival, and enhanced apoptosis compared to monotherapy in TNBC cells. RNA-seq studies demonstrated oncogenic/survival signaling pathways activated by HDACi were attenuated by the EC359 + HDACi therapy. Importantly, combination therapy potently inhibited the growth of TNBC patient derived explants, cell derived xenografts and patient-derived xenografts in vivo. Collectively, our results suggest that targeted inhibition of LIFR can enhance the therapeutic efficacy of HDACi in TNBC.",

author = "Mengxing Li and Suryavathi Viswanadhapalli and Bindu Santhamma and Pratap, {Uday P.} and Yiliao Luo and Junhao Liu and Altwegg, {Kristin A.} and Weiwei Tang and Zexuan Liu and Xiaonan Li and Behnam Ebrahimi and Hui Yan and Yi Zou and Swapna Konda and Sareddy, {Gangadhara R.} and Zhenming Xu and Yidong Chen and Rao, {Manjeet K.} and Brenner, {Andrew J.} and Kaklamani, {Virginia G.} and Tekmal, {Rajeshwar R.} and Gulzar Ahmed and Raj, {Ganesh V.} and Nickisch, {Klaus J.} and Nair, {Hareesh B.} and Vadlamudi, {Ratna K.}",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1038/s42003-021-02741-7",

language = "English (US)",

volume = "4",

journal = "Communications Biology",

issn = "2399-3642",

publisher = "Springer Nature",

number = "1",

}

TY - JOUR

T1 - LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer

AU - Li, Mengxing

AU - Viswanadhapalli, Suryavathi

AU - Santhamma, Bindu

AU - Pratap, Uday P.

AU - Luo, Yiliao

AU - Liu, Junhao

AU - Altwegg, Kristin A.

AU - Tang, Weiwei

AU - Liu, Zexuan

AU - Li, Xiaonan

AU - Ebrahimi, Behnam

AU - Yan, Hui

AU - Zou, Yi

AU - Konda, Swapna

AU - Sareddy, Gangadhara R.

AU - Xu, Zhenming

AU - Chen, Yidong

AU - Rao, Manjeet K.

AU - Brenner, Andrew J.

AU - Kaklamani, Virginia G.

AU - Tekmal, Rajeshwar R.

AU - Ahmed, Gulzar

AU - Raj, Ganesh V.

AU - Nickisch, Klaus J.

AU - Nair, Hareesh B.

AU - Vadlamudi, Ratna K.

PY - 2021/12

Y1 - 2021/12

N2 - Histone deacetylase inhibitors (HDACi) are identified as novel therapeutic agents, however, recent clinical studies suggested that they are marginally effective in treating triple negative breast cancer (TNBC). Here, we show that first-in-class Leukemia Inhibitory Factor Receptor (LIFRα) inhibitor EC359 could enhance the therapeutic efficacy of HDACi against TNBC. We observed that both targeted knockdown of LIFR with CRISPR or treatment with EC359 enhanced the potency of four different HDACi in reducing cell viability, cell survival, and enhanced apoptosis compared to monotherapy in TNBC cells. RNA-seq studies demonstrated oncogenic/survival signaling pathways activated by HDACi were attenuated by the EC359 + HDACi therapy. Importantly, combination therapy potently inhibited the growth of TNBC patient derived explants, cell derived xenografts and patient-derived xenografts in vivo. Collectively, our results suggest that targeted inhibition of LIFR can enhance the therapeutic efficacy of HDACi in TNBC.

AB - Histone deacetylase inhibitors (HDACi) are identified as novel therapeutic agents, however, recent clinical studies suggested that they are marginally effective in treating triple negative breast cancer (TNBC). Here, we show that first-in-class Leukemia Inhibitory Factor Receptor (LIFRα) inhibitor EC359 could enhance the therapeutic efficacy of HDACi against TNBC. We observed that both targeted knockdown of LIFR with CRISPR or treatment with EC359 enhanced the potency of four different HDACi in reducing cell viability, cell survival, and enhanced apoptosis compared to monotherapy in TNBC cells. RNA-seq studies demonstrated oncogenic/survival signaling pathways activated by HDACi were attenuated by the EC359 + HDACi therapy. Importantly, combination therapy potently inhibited the growth of TNBC patient derived explants, cell derived xenografts and patient-derived xenografts in vivo. Collectively, our results suggest that targeted inhibition of LIFR can enhance the therapeutic efficacy of HDACi in TNBC.

UR - http://www.scopus.com/inward/record.url?scp=85118460489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85118460489&partnerID=8YFLogxK

U2 - 10.1038/s42003-021-02741-7

DO - 10.1038/s42003-021-02741-7

M3 - Article

C2 - 34716410

AN - SCOPUS:85118460489

SN - 2399-3642

VL - 4

JO - Communications Biology

JF - Communications Biology

IS - 1

M1 - 1235

ER -

LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto